Bluebird Improves Patient Safety, Cuts Costs and Increases Revenue
Safe, effective treatment is almost always cost-effective. Cost arguments therefore follow consideration of the systematic quality and safety
improvement unlocked by Bluebird. Increasingly, healthcare associated infections are not being covered by funders. Bluebird provides the means for clinicians and managers to decrease the
absolute number of HAIs in your hospital. MDROs in your hospital are much more expensive to treat. According to Roberts et al. the additional medical costs for the treatment of antibiotic
resistant infections, including costs associated with increased duration of stay, comorbidities, ICU, surgery, and mortality, ranged from US$ 18,588 to US$ 29,069 per patient! Bluebird
aggressively manages and decreases the absolute number of MDRO's in your hospital. While inappropriate antibiotic prescribing contributes substantially to the number MDRO's in your hospital,
inappropriate prescribing also has direct, annual costs of approximately US$ 300 000 per hospital (30% of the hospital's antibiotic spend). Bluebird eliminates this direct cost.